Pfizer said Feb. 2 that it expects to sell about $15 billion worth of COVID-19 vaccines this year, CNBC reports.
The drugmaker said it expects an adjusted pretax profit in the high 20 percent range of revenue for the vaccine, according to CNBC. It forecasted its total 2021 revenue to be $59.4 billion to $61.4 billion.
In the fourth quarter of 2020, Pfizer saw $11.68 billion in revenue versus an expected $11.43 billion. That's a 12 percent increase over the same period the year prior, according to CNBC.
Read the full article here.
More articles on pharmacy:
US COVID-19 vaccinations exceed positive tests for virus, Bloomberg reports
One-third of nursing home staff vaccinated under federal pharmacy partnership
J&J vaccine helpful despite lower efficacy rate, Fauci says